Colorectal Cancer: Regorafenib in Adults ≥ 70 Years with Metastatic Colorectal CancerResearch Question:
How does the drug regorafenib effect quality of life and other issues relevant to
the elderly when given to adults age 70 or older to treat their colorectal cancer?
Basic Study Information
Purpose:Location: cancer center
The standard treatment for metastatic colorectal cancer usually includes chemotherapy
which can have side effects that are more difficult to tolerate for older patients
with cancer. Regorafenib (a non-chemotherapy option) was recently approved by the
FDA for treatment of patients whose cancer had grown on all standard chemotherapy
This study is being done among elderly patients, whose cancer has grown on all chemotherapy
agents or who are not able to tolerate chemotherapy, to measure the safety of regorafenib
in the elderly population and to assess how well the drug controls cancer growth.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02466009?term=02466009&rank=1
Study Reference #: UGIC-14072
Lead Researcher (Principal Investigator)
Lead Researcher: Mohamedtaki Tejani, MD
Study Contact InformationStudy Coordinator: Tanya Smith
Phone: (585) 275-8213
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search